Trials / Completed
CompletedNCT03632668
Evaluating the Pharmacokinetic Interaction Between AD-2071 and AD-2072
An Open-label, Two-period, One-sequence, Multiple Dosing Crossover Clinical Trial to Evaluate the Pharmacokinetic Interaction Between AD-2071 and AD-2072 in Healthy Male Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 38 (actual)
- Sponsor
- Addpharma Inc. · Industry
- Sex
- Male
- Age
- 19 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate the Pharmacokinetic Interaction Between AD-2071 and AD-2072 in healthy male volunteers.
Detailed description
To evaluate the pharmacokinetic Interaction, safety and tolerability of the combination compared with the administration of AD-2071 and AD-2072.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AD-2071 10/20mg | AD-2071 10/20 mg tablet |
| DRUG | AD-2072 80/5mg | AD-2072 80/5mg tablet |
| DRUG | AD-2071 10/20mg + AD2072 80/5mg | AD-2071 10/20 mg + AD-2072 80/5mg tablet |
Timeline
- Start date
- 2018-09-28
- Primary completion
- 2019-01-24
- Completion
- 2019-01-24
- First posted
- 2018-08-15
- Last updated
- 2019-07-05
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT03632668. Inclusion in this directory is not an endorsement.